Now showing items 362-381 of 3553

    • Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer? 

      Bhattacharya, IS; Kirby, AM; Bliss, JM; Coles, CE (2018-03)
      Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast cancer care have resulted in a substantial reduction in local ...
    • Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? 

      Carden, CP; Sarker, D; Postel-Vinay, S; Yap, TA; Attard, G; Banerji, U; Garrett, MD; Thomas, GV; Workman, P; Kaye, SB; de Bono, JS (2010-02)
      Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to ...
    • Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. 

      Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; Bliss, JM; Kirby, AM; IMPORT Trialists (2019-05)
      BACKGROUND:In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ...
    • Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. 

      Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; Bliss, JM (2017-11-23)
      Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants ...
    • Cancer across the tree of life: cooperation and cheating in multicellularity 

      Maley, Carlo; Aktipis, Athena (2015-07)
      Multicellularity is characterized by cooperation among cells for the development, maintenance and reproduction of the multicellular organism. Cancer can be viewed as cheating within this cooperative multicellular system. ...
    • Cancer and genomics 

      Stratton, M (2001-02)
      Cancer and genomics. Identification of the genes that cause oncogenesis is a central aim of cancer research. We searched the proteins predicted from the draft human genome sequence for paralogues of known tumour suppressor ...
    • Cancer care in the developed world: A comparison of surgical oncology training programs 

      Qadan, M; Davies, AR; Polk, HC; Allum, WH; Brennan, MF (Elsevier BV, 2018-01)
    • Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3. 

      Chambers, JS; Brend, T; Rabbitts, TH (2019-06-12)
      Many tumour causing proteins, such as those expressed after chromosomal translocations or from point mutations, are intracellular and are not enzymes per se amenable to conventional drug targeting. We previously demonstrated ...
    • Cancer cell transmission via the placenta. 

      Greaves, M; Hughes, W (2018-01)
      Cancer cells have a parasitic propensity in the primary host but their capacity to transit between individuals is severely restrained by two factors: a lack of a route for viable cell transfer and immune recognition in ...
    • Cancer epidemiology in the last century and the next decade 

      Peto, J (MACMILLAN PUBLISHERS LTD, 2001-05-17)
      By the early 1980s, epidemiologists had identified many important causes of cancer. They had also proposed the ‘multi-stage’ model of cancer, although none of the hypothesized events in human carcinogenesis had then been ...
    • Cancer genetics and reproduction 

      Hanson, Helen (ELSEVIER SCI LTD, 2010-02)
      Cancers of the reproductive organs (i.e., ovaries, uterus and testes), like other cancers, occur as a result of a multi-stage interaction of genetic and environmental factors. A small proportion of cancers of the reproductive ...
    • Cancer genetics, precision prevention and a call to action. 

      Turnbull, C; Sud, A; Houlston, RS (2018-09)
      More than 15 years have passed since the identification, through linkage, of 'first-wave' susceptibility genes for common cancers (BRCA1, BRCA2, MLH1 and MSH2). These genes have strong frequency-penetrance profiles, such ...
    • The cancer genome 

      Stratton, M (2009-04)
      All cancers arise as a result of changes that have occurred in the DNA sequence of the genomes of cancer cells. Over the past quarter of a century much has been learnt about these mutations and the abnormal genes that ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05)
      Context:Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. Objective:To examine cancer risks in relation to GH ...
    • Cancer survival is dependent on season of diagnosis and sunlight exposure 

      Lim, H-S; Roychoudhuri, R; Peto, J; Schwartz, G; Baade, P; Moller, H (WILEY-LISS, 2006-10-01)
      Sunlight is essential for the production of vitamin D in the body. Evidence exists to suggest that vitamin D metabolites may have a role in tumor growth suppression. In this large study, involving over a million cancer ...
    • Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. 

      Garrett, A; Callaway, A; Durkie, M; Cubuk, C; Alikian, M; Burghel, GJ; Robinson, R; Izatt, L; Talukdar, S; Side, L; Cranston, T; Palmer-Smith, S; Baralle, D; Berry, IR; Drummond, J; Wallace, AJ; Norbury, G; Eccles, DM; Ellard, S; Lalloo, F; Evans, DG; Woodward, E; Tischkowitz, M; Hanson, H; Turnbull, C; CanVIG-UK (2020-03-13)
      Advances in technology have led to a massive expansion in the capacity for genomic analysis, with a commensurate fall in costs. The clinical indications for genomic testing have evolved markedly; the volume of clinical ...
    • Cancer-Selective Targeting of the NF-kappa B Survival Pathway with GADD45 beta/MKK7 Inhibitors 

      Morgan, G (2014-10)
      Constitutive NF-B-K signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-B-K-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the ...
    • CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. 

      Bridgett, S; Campbell, J; Lord, CJ; Ryan, CJ (2017-07-12)
      Genes whose function is selectively essential in the presence of cancer-associated genetic aberrations represent promising targets for the development of precision therapeutics. Here, we present CancerGD, a resource that ...
    • Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis. 

      Sud, A; Hemminki, K; Houlston, RS (2017-03)
      To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-analysis of published case-control studies. Of ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, A-T; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TVO; Gerdes, A-M; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DGR; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; EMBRACE; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; GEMO Study Collaborators; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TAM; Meijers-Heijboer, HEJ; van der Hout, AH; Vreeswijk, MPG; Hoogerbrugge, N; Ausems, MGEM; van Doorn, HC; Collée, JM; HEBON; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, M-KM; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PDP; Chenevix-Trench, G; KConFab Investigators; Antoniou, AC; Friedman, E (2015-01)
      BACKGROUND:BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation ...